|
|
|
|
LEADER |
01000caa a22002652 4500 |
001 |
CTG004784316 |
003 |
DE-627 |
005 |
20230629100629.0 |
007 |
cr uuu---uuuuu |
008 |
210507s2023 xx |||||o 00| ||eng c |
035 |
|
|
|a (DE-627)CTG004784316
|
035 |
|
|
|a (UBBS_Klinische_Studien_WHO)EUCTR2012-004322-24-BE
|
035 |
|
|
|a (UBBS_Klinische_Studien_WHO)ARN-509-003
|
035 |
|
|
|a (UBBS_Klinische_Studien_WHO)2012-004322-24-AT
|
040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
041 |
|
|
|a eng
|
245 |
1 |
0 |
|a A Clinical study to assess the safety and effectiveness of ARN-509 in men with Castration-Resistant Prostate Cancer (prostate cancer not responsive to castration treatment)
|b A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men with Non-Metastatic (M0) Castration-Resistant Prostate Cancer - SPARTAN
|
264 |
|
1 |
|c 2023
|
336 |
|
|
|a Text
|b txt
|2 rdacontent
|
337 |
|
|
|a Computermedien
|b c
|2 rdamedia
|
338 |
|
|
|a Online-Ressource
|b cr
|2 rdacarrier
|
500 |
|
|
|a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 23-07-2013, Last updated: 2023-06-29
|
650 |
|
4 |
|a Medical Condition: Castration-Resistant Prostate Cancer MedDRA version: 21.1Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps);Therapeutic area: Diseases [C] - Cancer [C04]
|
650 |
|
4 |
|a Study Type: Interventional
|
650 |
|
4 |
|a Phase: Phase 3
|
650 |
|
4 |
|a Recruitment Status: Authorised-recruitment may be ongoing or finished
|
650 |
|
4 |
|a 610
|
773 |
0 |
8 |
|i Enthalten in
|t WHO International Clinical Trials Registry Platform
|g (2023) vom: 21. Juni
|
773 |
1 |
8 |
|g year:2023
|g day:21
|g month:06
|
856 |
4 |
0 |
|u https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-004322-24
|z kostenfrei
|3 Volltext
|
912 |
|
|
|a GBV_CTG
|
951 |
|
|
|a AR
|
952 |
|
|
|j 2023
|b 21
|c 06
|